BioWorld by Clarivate Highlights Gaps in Women's Health Research and Investment in New Special Series
BioWorld, published by Clarivate (NYSE:CLVT), has launched 'Healing the Health Divide,' a seven-part series examining disparities in women's health research and funding. The series reveals that only 15% of venture capital funding in 2023 went to women's health-focused biopharma companies, while just 8% of funded companies included women's health assets. Key findings show that women's health deals since 2019 represent only 18.5% of all analyzed deals from 473 companies.
The series explores gender bias in research, untapped market potential, and efforts to improve diagnosis and treatment of conditions like endometriosis and cardiovascular disease, which disproportionately affect women.
BioWorld, pubblicato da Clarivate (NYSE:CLVT), ha lanciato 'Healing the Health Divide', una serie in sette parti che esamina le disparità nella ricerca e nel finanziamento della salute delle donne. La serie rivela che solo il 15% dei finanziamenti di capitale di rischio nel 2023 è andato a aziende biopharma focalizzate sulla salute femminile, mentre solo l'8% delle aziende finanziate includeva attività legate alla salute delle donne. I risultati chiave mostrano che le transazioni relative alla salute delle donne dal 2019 rappresentano solo il 18,5% di tutte le transazioni analizzate provenienti da 473 aziende.
La serie esplora il bias di genere nella ricerca, il potenziale di mercato non sfruttato e gli sforzi per migliorare la diagnosi e il trattamento di condizioni come l'endometriosi e le malattie cardiovascolari, che colpiscono in modo sproporzionato le donne.
BioWorld, publicado por Clarivate (NYSE:CLVT), ha lanzado 'Healing the Health Divide', una serie de siete partes que examina las disparidades en la investigación y la financiación de la salud de las mujeres. La serie revela que solo el 15% de la financiación de capital de riesgo en 2023 fue a empresas biopharma enfocadas en la salud femenina, mientras que solo el 8% de las empresas financiadas incluían activos de salud de la mujer. Los hallazgos clave muestran que los acuerdos de salud femenina desde 2019 representan solo el 18.5% de todos los acuerdos analizados de 473 empresas.
La serie explora el sesgo de género en la investigación, el potencial de mercado no aprovechado y los esfuerzos por mejorar el diagnóstico y tratamiento de afecciones como la endometriosis y las enfermedades cardiovasculares, que afectan desproporcionadamente a las mujeres.
BioWorld는 Clarivate (NYSE:CLVT)에서 발행되며, 여성 건강 연구 및 자금 조달의 불균형을 조사하는 7부작 시리즈인 'Healing the Health Divide'를 시작했습니다. 이 시리즈는 2023년 벤처 캐피탈 자금의 15%만이 여성 건강에 초점을 맞춘 생명공학 회사에 분배되었으며, 자금 지원을 받은 회사 중 단 8%만이 여성 건강 자산을 포함하고 있음을 보여줍니다. 주요 발견에 따르면, 2019년 이후 여성 건강 관련 거래는 473개 회사의 모든 분석된 거래의 18.5%에 불과합니다.
이 시리즈는 연구에서의 성별 편견, 미활용 시장 잠재력, 그리고 여성에게 불균형적으로 영향을 미치는 자궁내막증 및 심혈관 질환과 같은 질병의 진단 및 치료 개선 노력을 탐구합니다.
BioWorld, publié par Clarivate (NYSE:CLVT), a lancé 'Healing the Health Divide', une série en sept parties examinant les disparités dans la recherche et le financement de la santé des femmes. La série révèle que seulement 15% du financement de capital-risque en 2023 a été attribué à des entreprises biopharmaceutiques axées sur la santé des femmes, tandis que seulement 8% des entreprises financées incluaient des actifs de santé féminine. Les découvertes clés montrent que les transactions liées à la santé des femmes depuis 2019 représentent seulement 18,5% de toutes les transactions analysées parmi 473 entreprises.
La série explore les biais de genre dans la recherche, le potentiel de marché inexploité et les efforts pour améliorer le diagnostic et le traitement de conditions telles que l'endométriose et les maladies cardiovasculaires, qui touchent de manière disproportionnée les femmes.
BioWorld, veröffentlicht von Clarivate (NYSE:CLVT), hat 'Healing the Health Divide' ins Leben gerufen, eine siebenteilige Serie, die Ungleichheiten in der Forschung und Finanzierung der Gesundheit von Frauen untersucht. Die Serie zeigt, dass im Jahr 2023 nur 15% des Risikokapitals in biopharmazeutische Unternehmen mit Fokus auf die Gesundheit von Frauen floss, während nur 8% der finanzierten Unternehmen Gesundheitskapital für Frauen beinhalteten. Die zentrale Erkenntnis zeigt, dass Transaktionen im Bereich der Gesundheit von Frauen seit 2019 nur 18,5% aller aus 473 Unternehmen analysierten Transaktionen ausmachen.
Die Serie beleuchtet Geschlechtervorurteile in der Forschung, ungenutztes Marktpotential und Bemühungen zur Verbesserung der Diagnose und Behandlung von Erkrankungen wie Endometriose und Herz-Kreislauf-Erkrankungen, die Frauen unverhältnismäßig betreffen.
- None.
- None.
Insights
The series highlights significant market inefficiencies in women's health investment, with only
The revealed funding gap, combined with the large addressable market in conditions like endometriosis (affecting 190 million women globally) and Alzheimer's (affecting women at twice the rate of men), suggests significant untapped potential for companies that can successfully address these underserved markets. For Clarivate, this publication positions them as a thought leader in identifying market opportunities and could drive increased interest in their healthcare analytics services.
New seven-part series explores disparities in care, funding and innovation impacting half the world's population
Women make up half of the global population, yet their health remains consistently underserved. Research and treatments have traditionally focused on reproduction and breast health, but these areas represent just a fraction of the broader health challenges women face. From autoimmune disorders to cardiovascular disease, many conditions disproportionately affect women or manifest differently than in men. However, decades of research have excluded women from clinical trials, often due to misconceptions about their "complex physiology." Meanwhile, male-dominated boardrooms have perpetuated this oversight in funding decisions, exacerbating the issue.
The consequences of this systemic neglect are stark. In 2023, just
Lynn Yoffee, Publisher of BioWorld, stated: "The new BioWorld special series, 'Healing the Health Divide,' is a call to action to address the inequities in women's health research and investment. The data we've uncovered highlights the urgent need for a paradigm shift in how we approach this critical issue. This series not only exposes the disparities but also celebrates the progress being made, with the goal of inspiring industry leaders and scientists to close these gaps and create solutions that benefit all of humanity."
The series explores underrecognized areas such as the role of gender bias in research, the untapped potential of women's health markets, and groundbreaking efforts to improve early diagnosis and treatment of conditions like endometriosis and cardiovascular disease.
Featured articles in 'Healing the Health Divide,' include:
- Despite women's health inroads, lackluster funding impedes progress
Despite increased interest, progress in women's health remains hindered by lackluster funding and decades of exclusion from clinical trials. The number of deals focused on women's health since 2019 comprise just18.5% of all deals analyzed from the 473 companies and they make up just20% of the total value of all deals that disclosed terms. This article, by Senior Managing Editor Karen Carey explores the inspiring efforts of women leading the charge to improve health outcomes and secure investments for female-focused solutions. - Dynamic infographic on Women's Health
A compelling visual analysis by Production Editor Ann Marie Griffith of women's health funding, showcases how venture capital and biopharma companies are beginning to address the vast unmet need — but still have far to go. - VCs emerge for women's health and its 'groundbreaking' research
WhileU.S. government initiatives are supportive, private market investments are essential to advance women's health innovations. This article highlights emerging venture capital efforts and the challenges of securing funding. - The science of gender-based medicine: many reasons, many manifestations
From Alzheimer's to autoimmune diseases, Managing Editor Anette Breindl, examines how biological and hormonal differences impact disease prevalence and progression in women, emphasizing the importance of gender-specific medical research. - Gender bias leaves women at risk in cardiology treatment guidelines
Gender bias in cardiac care has left nearly70% of women underdiagnosed for cardiovascular disease. Staff Writer Tamra Sami investigates how male-focused clinical trials have skewed treatment guidelines, endangering women's lives. - Holistic strategies needed to diagnose and treat endometriosis
Endometriosis affects10% of women globally, yet delayed diagnosis and limited understanding have left millions suffering unnecessarily. This article, also produced by Sami, delves into the biological complexity of the disease and the need for comprehensive treatment strategies. - New diagnostics, trials address deadly disparities in women's cardiac care
While women with "big hearts" play well in popular culture, cardiologists see a very different picture – with significant implications for women's health and medical care, according to an article by Editor Annette Boyle. Women have smaller hearts and smaller blood vessels than men and their cardiovascular systems respond to disease and treatment in very different ways. In 2024, for the first time, major trials of cardiovascular medical devices sought to understand how common interventions work in women and how previous failures to include women in studies translated into higher cardiovascular mortality rates.
BioWorld's "Healing the Health Divide" underscores the urgent need for equitable investment in women's health and celebrates the pioneers driving meaningful change.
To access the full special series, visit https://www.bioworld.com/womens_health.
Join the conversation and mention BioWorld on X and LinkedIn as well as Clarivate for Life Sciences & Healthcare on X and LinkedIn.
About BioWorld
With writers and editors stationed around the globe, BioWorld published by Clarivate, reports the breaking news - and provides key perspective on hundreds of therapeutics and devices in development, the companies behind those candidates, the business development transactions that evolve the markets, and the regulatory hurdles that both challenge and guard the processes. BioWorld has a long tradition of excellence in journalism. Collectively, the news services have been honored with 61 awards dating back to 1998.
About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com
Media Contact
Catherine Daniel
Director, External Communications, Life Sciences & Healthcare, Clarivate
newsroom@clarivate.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/bioworld-by-clarivate-highlights-gaps-in-womens-health-research-and-investment-in-new-special-series-302312175.html
SOURCE Clarivate Plc
FAQ
What percentage of venture capital funding went to women's health companies in 2023 according to Clarivate (CLVT)?
What percentage of funded companies had women's health assets in their pipelines as reported by Clarivate (CLVT)?
What percentage of deals since 2019 were focused on women's health according to Clarivate's (CLVT) BioWorld report?
What is the focus of BioWorld's 'Healing the Health Divide' series by Clarivate (CLVT)?
